Johnson & Johnson is paying $5.5 billion and admitting nothing. Both halves of that sentence matter.
The settlement announced today covers roughly 76,000 US lawsuits alleging that talc-based products caused ovarian cancer - nearly every remaining claim in the federal court in New Jersey and the related state cases [1].
It takes effect only if at least 95 percent of remaining claimants sign on [1]. That is a high bar, and a deliberate one: a company buying peace wants to buy all of it.
The company's own framing is that it would have won. A J&J spokesman said the firm was 'confident the Company would have ultimately prevailed with further litigation' [1].
That is a defensible thing for a defendant to say. It is worth noticing what it is not. It is not a statement that the talc was safe, offered in the same breath as a $5.5 billion payment.
The number that explains the timing came from the other side.
Lead plaintiffs' counsel Chris Seeger described 'more than a decade of protracted litigation and three failed bankruptcies' [1].
Three.
The strategy those filings represent has a name in the trade: a corporate restructuring that moves the liabilities of a solvent parent into a new subsidiary, then puts that subsidiary into Chapter 11 - so that tens of thousands of jury trials become one bankruptcy proceeding. Courts rejected it three times.
What ended a decade of litigation was not new science and not a change of heart. It was the exhaustion of a procedural route.
J&J pulled talc-based baby powder from US and Canadian shelves in 2020, saying then that the product was safe [1].
It is not over abroad. A UK action filed in 2025 involves roughly 3,000 claimants and estimated damages above 1 billion pounds [1].
One thing this newsroom is not doing: adjudicating whether talc causes ovarian cancer. We are recording what a company that says it would have won agreed to pay - and how many attempts to avoid a jury it took first.
